DENVER, CO / ACCESS Newswire / / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...

Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and ...

Aytu BioPharma (NASDAQ:AYTU) is preparing to release its quarterly earnings on Thursday, 2025-11-13. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Management expects the EXXUA launch in the fourth quarter of calendar 2025, with product availability by year-end and initial physician detailing planned for the first calendar quarter of 2026.

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. The offering is expected to close on or about June 9, 2025, subject to ...

Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at [email protected] to schedule one-on-one meetings with Aytu's management. If you would like ...

Josh Disbrow, Chief Executive Officer of Aytu BioScience, Inc., stated, "We've built considerable momentum since our formation in April of last year, and we believe we are poised for significant ...

DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...